Innoviva (INVA) Cash from Investing Activities Growth (1y) (2011 - 2026)

Innoviva (INVA) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 62.68%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -674.01%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -166.24%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Innoviva 1.58 Bn 979.49 Mn 75.83 Mn 206.73%

Historic Data

Download Data
DateValue
Mar 31, 2026 206.73%
Sep 30, 2025 134.90%
Mar 31, 2025 19.43%
Sep 30, 2024 21.59%
Mar 31, 2024 -20.48%
Sep 30, 2023 -28.47%
Mar 31, 2023 75.05%
Sep 30, 2022 -175.37%
Jun 30, 2022 -102.80%
Mar 31, 2022 -442.38%
Sep 30, 2021 848.55%
Jun 30, 2021 1,386.01%
Mar 31, 2021 -264.51%
Dec 31, 2020 -706.76%
Sep 30, 2020 46.66%
Jun 30, 2020 -134.81%
Mar 31, 2020 121.63%
Dec 31, 2019 214.04%
Sep 30, 2019 -217.86%
Jun 30, 2019 121.49%